Pfizer (NYSE:PFE – Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14, Briefing.com reports. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period in the previous year, the business earned $0.67 EPS. Pfizer’s revenue was up 2.1% compared to the same quarter last year. Pfizer updated its FY 2024 guidance to 2.450-2.650 EPS.
Pfizer Trading Down 2.7 %
Pfizer stock traded down $0.85 during mid-day trading on Wednesday, hitting $30.54. The company’s stock had a trading volume of 40,944,947 shares, compared to its average volume of 40,093,852. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market cap of $173.06 billion, a price-to-earnings ratio of -509.00, a price-to-earnings-growth ratio of 1.20 and a beta of 0.69. The business has a 50 day moving average price of $28.64 and a 200-day moving average price of $27.79. Pfizer has a 12 month low of $25.20 and a 12 month high of $37.19.
Pfizer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.50%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,800.00%.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on PFE
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
- Five stocks we like better than Pfizer
- ETF Screener: Uses and Step-by-Step Guide
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How to Invest in Insurance Companies: A GuideĀ
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Stock Analyst Ratings and Canadian Analyst Ratings
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.